Alkermes (ALKS) Net Income (2010 - 2026)

Alkermes (ALKS) posted quarterly Net Income of $524000.0 for Q2 2026, up 100.79% quarter-over-quarter from -$66.5 million in Q1 2026.

Alkermes (ALKS) Net Income (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Net Income for 17 consecutive years, with $524000.0 the latest figure, recorded in Q2 2026.

In Q2 2026, Net Income changed N/A year-over-year to $524000.0; the TTM figure through Jun 2026 stood at -$16.6 million (down 2699.53% YoY), while the FY2025 annual figure was $241.7 million, up 4273.82% from the prior year.
Net Income climbed to $524000.0 in Q2 2026 per ALKS's latest filing, from -$66.5 million in the prior quarter.
Across five years, Net Income topped out at $87.7 million in Q4 2022 and bottomed at -$66.5 million in Q1 2026.
Historically, Net Income has averaged -$15.3 million across 5 years, with a median of -$30.1 million in 2022.
Annual changes were most pronounced in 2022 — Net Income sank 1374.79% — and 2025, when it soared 4309.91%.
Alkermes' Net Income stood at $87.7 million in 2022, then sank by 146.58% to -$40.9 million in 2023, then jumped by 102.74% to $1.1 million in 2024, then jumped by 4309.91% to $49.4 million in 2025, then tumbled by 98.94% to $524000.0 in 2026.
Business Quant data shows ALKS's Net Income at $524000.0 in Q2 2026, -$66.5 million in Q1 2026, and $49.4 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	-576.00 Mn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	866.00 Mn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	-69.36 Mn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	333.00 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	-118.80 Mn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	144.40 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	54.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn	524,000.00

Download Data